GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » 5-Year RORE %

RCUS (Arcus Biosciences) 5-Year RORE % : 10.13% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Arcus Biosciences's 5-Year RORE % for the quarter that ended in Sep. 2024 was 10.13%.

The industry rank for Arcus Biosciences's 5-Year RORE % or its related term are showing as below:

RCUS's 5-Year RORE % is ranked better than
75.41% of 1106 companies
in the Biotechnology industry
Industry Median: -7.6 vs RCUS: 10.13

Arcus Biosciences 5-Year RORE % Historical Data

The historical data trend for Arcus Biosciences's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcus Biosciences 5-Year RORE % Chart

Arcus Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial - - -29.50 15.31 18.84

Arcus Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.76 18.84 8.36 5.45 10.13

Competitive Comparison of Arcus Biosciences's 5-Year RORE %

For the Biotechnology subindustry, Arcus Biosciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcus Biosciences's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's 5-Year RORE % falls into.



Arcus Biosciences 5-Year RORE % Calculation

Arcus Biosciences's 5-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -3.15--1.91 )/( -12.24-0 )
=-1.24/-12.24
=10.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 5-year before.


Arcus Biosciences  (NYSE:RCUS) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Arcus Biosciences 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Arcus Biosciences's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcus Biosciences Business Description

Traded in Other Exchanges
N/A
Address
3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Executives
Alexander Azoy officer: Chief Accounting Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Jennifer Jarrett officer: See Remarks C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Juan C. Jaen director, 10 percent owner, officer: President 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Goeltz Ii Robert C. officer: Chief Financial Officer 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Terry J Rosen director, 10 percent owner, officer: Chief Executive Officer C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang officer: General Counsel 3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten officer: Chief Medical Officer 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins director 3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert director 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman officer: Chief Medical Officer C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko director, 10 percent owner 509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman director 618 MIRADA AVE, STANFORD CA 94305